These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 2754015)

  • 21. Biotyping of micelial fungus cultures by the killer system.
    Polonelli L; Dettori G; Cattel C; Morace G
    Eur J Epidemiol; 1987 Sep; 3(3):237-42. PubMed ID: 3653352
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of growth factor deficiency on killer toxin sensitivity of Saccharomyces cerevisiae.
    Jirků V; Cejková A
    Z Allg Mikrobiol; 1981; 21(6):423-6. PubMed ID: 7027641
    [No Abstract]   [Full Text] [Related]  

  • 23. In vitro antimycotic activity of a Williopsis saturnus killer protein against food spoilage yeasts.
    Goretti M; Turchetti B; Buratta M; Branda E; Corazzi L; Vaughan-Martini A; Buzzini P
    Int J Food Microbiol; 2009 May; 131(2-3):178-82. PubMed ID: 19269052
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro antifungal susceptibilities of Sporothrix schenckii in two growth phases.
    Trilles L; Fernández-Torres B; Dos Santos Lazéra M; Wanke B; de Oliveira Schubach A; de Almeida Paes R; Inza I; Guarro J
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3952-4. PubMed ID: 16127080
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Killer toxin of Hanseniaspora uvarum.
    Radler F; Schmitt MJ; Meyer B
    Arch Microbiol; 1990; 154(2):175-8. PubMed ID: 2206104
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of a monoclonal killer anti-idiotypic antibody and a synthetic killer peptide against oral isolates of Candida spp. differently susceptible to conventional antifungals.
    Manfredi M; McCullough MJ; Conti S; Polonelli L; Vescovi P; Al-Karaawi ZM; Porter SR
    Oral Microbiol Immunol; 2005 Aug; 20(4):226-32. PubMed ID: 15943767
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of the in vitro antimycotic activity of a novel killer protein from Williopsis saturnus DBVPG 4561 against emerging pathogenic yeasts.
    Buzzini P; Corazzi L; Turchetti B; Buratta M; Martini A
    FEMS Microbiol Lett; 2004 Sep; 238(2):359-65. PubMed ID: 15358421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the killer toxin of several yeasts and the purification of a toxin of type K2.
    Pfeiffer P; Radler F
    Arch Microbiol; 1984 Apr; 137(4):357-61. PubMed ID: 6375620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro susceptibility of isolates of Sporothrix schenckii to amphotericin B, itraconazole, and terbinafine: comparison of yeast and mycelial forms.
    Kohler LM; Soares BM; de Assis Santos D; Da Silva Barros ME; Hamdan JS
    Can J Microbiol; 2006 Sep; 52(9):843-7. PubMed ID: 17110976
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transcriptome-wide expression profiling of
    Giosa D; Felice MR; Giuffrè L; Aiese Cigliano R; Paytuví-Gallart A; Lo Passo C; Barresi C; D'Alessandro E; Huang H; Criseo G; Mora-Montes HM; de Hoog S; Romeo O
    Microb Genom; 2020 Oct; 6(10):. PubMed ID: 33034552
    [No Abstract]   [Full Text] [Related]  

  • 31. Serological study of yeast killer toxins by monoclonal antibodies.
    Polonelli L; Manzara S; Conti S; Dettori G; Morace G; Chezzi C
    Mycopathologia; 1989 Dec; 108(3):211-5. PubMed ID: 2515441
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The viral killer system in yeast: from molecular biology to application.
    Schmitt MJ; Breinig F
    FEMS Microbiol Rev; 2002 Aug; 26(3):257-76. PubMed ID: 12165427
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular and cellular events during the yeast to mycelium transition in Sporothrix schenckii.
    Betancourt S; Torres-Bauzá LJ; Rodríguez-Del Valle N
    Sabouraudia; 1985 Jun; 23(3):207-18. PubMed ID: 4023887
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The costs and benefits of killer toxin production by the yeast Pichia kluyveri.
    Pintar J; Starmer WT
    Antonie Van Leeuwenhoek; 2003; 83(1):89-97. PubMed ID: 12755485
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Yeast cell cycle of Sporothrix schenckii.
    Resto S; Rodríguez-del Valle N
    J Med Vet Mycol; 1988 Feb; 26(1):13-24. PubMed ID: 3379537
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Physiological characters of Sporothrix schenckii isolates.
    Ghosh A; Maity PK; Hemashettar BM; Sharma VK; Chakrabarti A
    Mycoses; 2002 Dec; 45(11-12):449-54. PubMed ID: 12472719
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Killer systems and pathogenic fungi.
    Polonelli L; Morace G
    Eur J Epidemiol; 1988 Dec; 4(4):415-8. PubMed ID: 3203721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ultrastructural studies on the yeastlike and mycelial phases of Sporotrichum schenckii.
    Lane JW; Grrison RG; Field MF
    J Bacteriol; 1969 Nov; 100(2):1010-9. PubMed ID: 5354930
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro activity of monoclonal and recombinant yeast killer toxin-like antibodies against antibiotic-resistant gram-positive cocci.
    Conti S; Magliani W; Arseni S; Dieci E; Frazzi R; Salati A; Varaldo PE; Polonelli L
    Mol Med; 2000 Jul; 6(7):613-9. PubMed ID: 10997342
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Killer system: a simple method for differentiating Candida albicans strains.
    Polonelli L; Archibusacci C; Sestito M; Morace G
    J Clin Microbiol; 1983 May; 17(5):774-80. PubMed ID: 6345575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.